Phase 2b data show benefits of oral MK-0616 in hypercholesterolaemia YELLOW III supports aggressive lipid lowering to reduce plaque progression CLEAR Outcomes shows 13% reduction in CV events with bempedoic acid Olpasiran reduces Lp(a) irrespective of baseline Lp(a)AT-TARGET-IT: Real world data show high adherence to PCSK9 inhibitors Genetic variants in PCSK9 gene not linked to heart failure

From the Editors

Posted on 18 March 2014 |

Lipoprotein(a) and atrial fibrillation – Is there a link?

John chapman & Henry Ginsberg Profs. John Chapman and Henry Ginsberg discuss new data implicating Lp(a) as a potential causal mediator of atrial fibrillation.

Read the editorial

Related reports:

Updated lipoprotein(a) consensus paper

Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”

Does PCSK9 inhibition reduce the risk of venous thromboembolism?

Related content

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters